Australia markets close in 1 hour 34 minutes

PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.11000.0000 (0.00%)
As of 02:03PM AEST. Market open.

PYC Therapeutics Limited

Harry Perkins Institute of Medical Research
6 Verdun Street
Nedlands, WA 6009
Australia
61 8 6151 0992
https://pyctx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Executive Director437.5kN/A1983
Mr. Andrew Taylor B.Com., C.A.CFO & Company SecretaryN/AN/AN/A
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A.Company Secretary165.9kN/A1962
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Corporate governance

PYC Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.